However, I guess this high subscription fee means that a subscription to BioWorld is for the serious health industry players.
The below article was released to their subscribers last night (while there is not much to see in the summary below it does confirm that word is getting out to the target market)
Mesoblast prices pediatric stem cell treatment at $1.55 millionFeb. 27, 2025 By Tamra Sami
Regenerative medicine company Mesoblast Ltd. is preparing to launch its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil, (remestemcel-L), in March in the U.S. and has priced the treatment at roughly $1.55 million for a full course.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)